Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Cancer vaccine efficacy assessed using lynch syndrome model
A new strategy for developing vaccines against cancer showed promise in a proof-of-concept study led…
World-first trial tests cannabis-based drug on aggressive brain tumours
A major UK trial of cannabis-based drug Sativex in treating the most aggressive form of…
Lynch syndrome: Colorectal cancer vaccine successful in mice
Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first…
Paediatric cancer drug shows 93 percent response rate
A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.